

QUESTIONNAIRE FOR THE TESTING OF THE GUIDANCE ON RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

GENERAL INFORMATION ABOUT THE TESTING

Q1. These results are being submitted on behalf of a:	<input type="checkbox"/> Party. Please specify: <Turkmenistan> <input type="checkbox"/> Other Government. Please specify: <Country's name> <input type="checkbox"/> Organization. Please specify: <Organization's name>
Q2. When was the testing of the Guidance conducted?	Please enter date: <2010, 2011
Q3. Type of event where the testing of the Guidance was conducted?	<input type="checkbox"/> Group event (e.g., workshop, training course, meeting). Please provide the title of the event and name of organizer: <On the Asian Training Course on Risk Assessment of Living Modified Organisms Siem Reap, Cambodia, 12-16 July 2010; and after studying of the "Guidance on risk assessment on LMOType here> Type of meeting: <input checked="" type="checkbox"/> Face-to-face <input type="checkbox"/> Online <input type="checkbox"/> Individual exercise. Please provide your name, occupation and affiliation: <Kokanova Ejebay - NFP on Cartagena Protokol on Biosafety> <input type="checkbox"/> Other: Please specify: <Type here>
Q4. Which sections of the Guidance were tested?	<input checked="" type="checkbox"/> Part I: The Roadmap for Risk assessment of LMOs Part II: Specific types of LMOs or Traits: <input type="checkbox"/> Risk assessment of LMOs with stacked genes or traits <input checked="" type="checkbox"/> Risk assessment of LM crops with tolerance to abiotic stress <input checked="" type="checkbox"/> Risk assessment of LM mosquitoes

OVERALL EVALUATION

	Very poor	Poor	Neutral	Good	Very good
<i>Please indicate the level of agreement you attribute to each of the questions in the left column.</i>					
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in a <u>scientifically sound and case-by-case manner</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.

<p>Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?</p>	<p><input checked="" type="checkbox"/> Yes <input type="checkbox"/> No</p>	<p>Comments: <The Roadmap take into account the Article 15 and Annex III of the Protocol. The Guidance consider potential environmental risk assessment of LMO - one of the major aspects of Biosafety - the issue, that still have ongoing discussions among risk assessors, scientists.></p>
<p>Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?</p>	<p><input checked="" type="checkbox"/> Yes <input type="checkbox"/> No</p>	<p>Comments: <This Roadmap is very useful for risk assessors with limited experience, because first of all it shows how the risk assessment is complicated process that have to be done step by step.></p>
<p>Q10. Is the Roadmap organized in a logic and structured manner?</p>	<p><input checked="" type="checkbox"/> Yes <input type="checkbox"/> No</p>	<p>Comments: <Yes, the Roadmap organized in a structured manner, including logic steps - Phase for risk assessment process. The detailed explaining of necessary criterias for quality and relevance of information is important for RA.></p>
<p>Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?</p>	<p><input checked="" type="checkbox"/> Yes <input type="checkbox"/> No</p>	<p>Comments: <The Roadmap shows that RA is complex process and demand designing the environmental and health regulations and biosafety strategies and etc.></p>
<p>Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>	<p>Comments: <In general the Roadmap is applicable to LMO plants and animals (mosquitoes)></p>
<p>Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>	<p>Comments: <The Roadmap applicable to small and large scale releases into the environment and consider potential adverse effects that may result from changes due to the genetic modification(s).></p>
<p>Q14. Is there any other issue or concept that you would like to see included in the Roadmap?</p>	<p><input checked="" type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>	<p>Comments: <Type here></p>
<p>Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?</p>	<p><input checked="" type="checkbox"/> Yes <input type="checkbox"/> No</p>	<p>Comments: <The flowchart provide logic and graphic representation of RA process and facilitate the understanding the RA process.></p>

PART II: SPECIFIC TYPES OF LIVING MODIFIED ORGANISMS OR TRAITS

Risk assessment of living modified organisms with stacked genes or traits

Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.

Q16. Does this section provide useful guidance when conducting risk assessments of LMOs with stacked genes or traits in accordance with the Protocol? Yes No Comments: <Type here>

Q17. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LMOs with stacked genes or traits? Yes No Comments: <Type here>

Q18. Is this section of the Guidance organized in a logic and structured manner? Yes No Comments: <Type here>

Q19. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity? Yes No Comments: <Type here>

Q20. Is there any other issue or concept that you would like to see included in this section of the Guidance? Yes No Comments: <Type here>

Risk assessment of living modified crops with tolerance to abiotic stress

Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.

Q21. Does this section provide useful guidance when conducting risk assessments of LM crops with tolerance to abiotic stress(es) in accordance with the Protocol? Yes No Comments: <Type here>

Q22. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LM crops with tolerance to abiotic stress(es)? Yes No Comments: <Type here>

Q23. Is this section of the Guidance organized in a logic and structured manner? Yes No Comments: <Type here>

Q24. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity? Yes No Comments: <Type here>

Q25. Is there any other issue or concept that you would like to see included in this section of the Guidance? Yes No Comments: <Type here>

Risk assessment of living modified mosquitoes

Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.

Q26. Does this section provide useful guidance when conducting risk assessments of LM mosquitoes in accordance with the Protocol? Yes No Comments: <Type here>

Q27. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LM mosquitoes? Yes No Comments: <Type here>

Q28. Is this section of the Guidance organized in a logic and structured manner? Yes No Comments: <Type here>

Q29. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity? Yes No Comments: <Type here>

Q30. Is there any other issue or concept that you would like to see included in this section of the Guidance? Yes No Comments: <Type here>

ADDITIONAL COMMENTS

Please add any additional comment you may have regarding the "Guidance on Risk Assessment of Living Modified Organisms" below.

Q31. <It will be very interesting to get the information about Strategic Environment Assessment (SEA) developed by CBD and EU, that includes the additional aspects of RA.>
